OrthoVentions formalizes a strategic partnership with Thinktiv, enhancing musculoskeletal innovation commercialization. Leveraging extensive experience, they offer comprehensive services, exemplified by the success of their first investment, GeminiOV, setting a new standard for future innovations.
After a tremendously successful initial partnership on our first OrthoVentions investment—GeminiOV—we are ecstatic to share that OV has formalized an overarching strategic partnership with Thinktiv, the leading value-creation services firm for emerging technology product businesses.
With a near 20-year track record of delivering superior market outcomes for diverse MedTech and Healthcare businesses, Thinktiv brings a powerful combination of high-impact services that—when combined with OV’s already established status as the premier accelerator fund for musculoskeletal innovation within hospital systems— will fundamentally accelerate the commercialization and value creation trajectories of our portfolio investments.
THINKTIV PARTNERSHIP
Streamlining Strategic Services
Under the partnership, Thinktiv will provide OV and our portfolio companies with a single-source strategic partner for services spanning commercial go-to-market strategy, product strategy, user experience (UX) strategy & design, and corporate development & capital transactions advisory, enabling high-velocity, capital-efficient transformation of musculoskeletal surgical innovations into valuable businesses positioned for rapid growth and clinical impact.
GEMINIOV: BLUEPRINT FOR ACCELERATED GROWTH
Illustrating the Future of Musculoskeletal Innovation
Our first portfolio investment in GeminiOV illustrated the power of the partnership in terms of the speed at which that company’s innovation and IP were coupled to the product development process to support the regulatory approval and alignment with commercial and clinical needs. With the formalization of this relationship, that power will now extend, not only to future OV investments but as a model for how musculoskeletal innovations will be commercialized in the future.
